Article

Tau pathological binding activity in plasma before the onset of symptomatic Alzheimer’s disease

2026-04-04

Abstract excerpt

Alzheimer’s disease (AD) and other tauopathies are characterized by the hyperphosphorylation of tau (pTau), leading to its aggregation in the brain, a process strongly predictive of neurodegeneration and cognitive decline. Currently, tau positron emission tomography (PET) is the only validated method for detecting tau aggregates in vivo. However, its high cost, invasiveness, and limited accessibility restrict its...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 064a9daa-5c83-50a4-9511-1b4b66dd4743
DOI: 10.64898/2026.04.03.26350110

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Tau pathological binding activity in plasma before the onset of symptomatic Alzheimer’s diseaseDOI 10.64898/2026.04.03.26350110Read

Progress regarding the context-of-use of tau as biomarker of Alzheimer’s disease and other neurodegenerative diseasesSemantic proximity Read

Tau-mediated Neurodegeneration and Potential Implications in Diagnosis and Treatment of Alzheimer's DiseaseSemantic proximity Read

Pittsburgh plasma p-tau217: classification accuracies for autosomal dominant and sporadic Alzheimer’s disease in the communitySemantic proximity Read

Robustness of plasma p-Tau217 diagnostic thresholds for Alzheimer’s disease across various clinical populations and laboratory environmentsSemantic proximity Read

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.Semantic proximity Read

A plasma biomarker panel for detecting early amyloid-β accumulation and its changes in middle-aged cognitively unimpaired individuals at risk for Alzheimer’s diseaseSemantic proximity Read

ApoE4 lowers the ptau217 threshold for tau aggregation and spread in an allele dose-dependent manner.Semantic proximity Read

Plasma p-tau217 predicts cognitive impairments up to ten years before onset in normal older adultsSemantic proximity Read

The Alzheimers Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin studySemantic proximity Read

CNS-selective plasma p-tau217 accurately captures Alzheimer’s disease pathology and progressionSemantic proximity Read

Analytical and Clinical Validation of a High Accuracy Fully Automated Digital Immunoassay for Plasma Phospho-Tau 217 for Clinical Use in Detecting Amyloid PathologySemantic proximity Read

Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s diseaseSemantic proximity Read